Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
95.36
-3.76 (-3.79%)
At close: Apr 6, 2026, 4:00 PM EDT
95.54
+0.18 (0.19%)
After-hours: Apr 6, 2026, 7:33 PM EDT
Revolution Medicines Stock Forecast
Stock Price Forecast
The 17 analysts that cover Revolution Medicines stock have a consensus rating of "Strong Buy" and an average price target of $120.47, which forecasts a 26.33% increase in the stock price over the next year. The lowest target is $71 and the highest is $170.
Price Target: $120.47 (+26.33%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Revolution Medicines stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 9 | 8 | 8 | 9 | 8 |
| Buy | 9 | 9 | 9 | 9 | 9 | 9 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 18 | 18 | 17 | 17 | 18 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Strong Buy Initiates $88 → $140 | Strong Buy | Initiates | $88 → $140 | +46.81% | Mar 16, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $75 → $120 | Buy | Maintains | $75 → $120 | +25.84% | Feb 26, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $100 → $144 | Buy | Maintains | $100 → $144 | +51.01% | Feb 26, 2026 |
| Needham | Needham | Strong Buy Maintains $150 → $145 | Strong Buy | Maintains | $150 → $145 | +52.06% | Feb 26, 2026 |
| JP Morgan | JP Morgan | Buy Maintains $92 → $122 | Buy | Maintains | $92 → $122 | +27.94% | Feb 2, 2026 |
Financial Forecast
Revenue This Year
55.50M
Revenue Next Year
282.31M
from 55.50M
Increased by 408.69%
EPS This Year
-7.47
from -5.95
EPS Next Year
-6.48
from -7.47
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 262.5M | 939.7M | |||
| Avg | 55.5M | 282.3M | |||
| Low | n/a | 50.8M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | 1,593.2% | |||
| Avg | - | 408.7% | |||
| Low | - | -8.5% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -5.35 | -1.35 | |||
| Avg | -7.47 | -6.48 | |||
| Low | -8.21 | -8.27 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.